Biblio
BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma: a real-life experience. J Cancer Res Clin Oncol. 2022.
Brentuximab Vedotin and Chemotherapy in Relapsed/Refractory Hodgkin Lymphoma: a Propensity Score Matched Analysis. Blood Adv. 2024.
Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
Diffuse large B cell lymphoma characteristics and outcomes during the COVID-19 pandemic in two tertiary centers - an Israeli/ Italian study. Ann Hematol. 2023.
Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.
Elderly Non-GCB Diffuse Large B-Cell Lymphoma Patient Responding to Lenalidomide after Epicardial Relapse: A Case Report. Acta Haematol. 2020:1-4.
. Hepatosplenic T-cell non-Hodgkin lymphoma cured with tandem autologous and allogeneic stem cell transplantation. Chemotherapy. 2022.
. Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?. Curr Hematol Malig Rep. 2021.
. Management of relapsed/refractory mantle cell lymphoma: a review of current therapeutic strategies. Leuk Lymphoma. 2013.
. NR1H3 (LXRα) IS ASSOCIATED WITH PRO-INFLAMMATORY MACROPHAGES, PREDICTS SURVIVAL AND SUGGESTS POTENTIAL THERAPEUTIC RATIONALES IN DIFFUSE LARGE B-CELL LYMPHOMA. Hematol Oncol. 2022.
Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma. Leuk Lymphoma. 2019:1-7.
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leuk Lymphoma. 2020:1-5.
Peripheral T-cell lymphomas. Hematol Oncol. 2023;41 Suppl 1:82-87.
. Quality-of-life analysis of pembrolizumab vs brentuximab vedotin for relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2021.
Successful Bridging to Allogeneic Transplantation With Valemetostat in Two Refractory/relapsed Peripheral T-cell lymphoma patients. Mediterr J Hematol Infect Dis. 2024;16(1):e2024004.
. .